NCT06728410View on ClinicalTrials.gov

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Interventions
DRUG

Pemigatinib

Pemigatinib 13.5 mg

DRUG

Durvalumab

Durvalumab 1500 mg IV

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

collaborator

University of Alabama at Birmingham

OTHER

lead

Mehmet Akce

OTHER